Elixir drops IPO, Aldagen launches IPO

Elixir Pharmaceuticals has dropped its bid for an $86 million IPO, saying that market conditions aren't right. At the same time, Aldagen, a small biotech company with 18 employees, is making a bid to raise $80 million in an IPO. Aldagen is developing adult stem cell therapies.

The News & Observer notes that if Aldagen is successful, it will raise new funds for research while setting up an exit for its investors. The developer was set up in 2000 to exploit new research at Duke.

- check out the report on Elixir
- see Aldagen's release and read the story for more

Related Articles:
Aldagen gets $18.4M in fourth round
Aldagen adds $9M in new venture funds
Aldagen gains $17.3M in financing
Elixir Pharmaceuticals plans $86.25M IPO

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.